Ageas: AG Real Estate looking to reduce exposure to Interparking, lower capital charges. Air France-KLM: 3Q25 a bit light? ASML: Preview 3Q25, riding the AI wave. Barco: Preview 3Q25, self-help offsets macro headwind. D'Ieteren: Belron starts to roll out static mobile recalibration. Euronext: September's seasonal recovery. Tessenderlo More focus on capital allocation and returns. TomTom: Preview 3Q25, Cost cutting offsets slow markets. Umicore: Gold inventory sale-and-lease-back
Ageas: Highlights ING Benelux Conference London. Alfen: Highlights from ING Benelux Conference London. Arcadis: Highlights ING Benelux Conference London. ASR: Highlights ING Benelux Conference London. BAM: Highlights ING Benelux Conference London. Basic-Fit: Highlights ING Benelux Conference London. CTP: Highlights from ING Benelux Conference London. DEME Group: Highlights ING Benelux Conference London. Fugro: Highlights ING Benelux Conference London. Heijmans: Highlights ING Bene...
Next to a few one-off elements that inflated the headline 1H25 numbers, Ageas noted some strong underlying drivers, leading to several guidance upgrades. Incorporating these elements in our SoTP, we land on a new TP of €62. We feel 1H25 results have underpinned the 27% share rally the stock has seen this year, but we find it harder to see further upside potential at this stage. UK market pricing is again a question mark and BNP & Ethias could cause some negative news flow going forward. Given li...
The outlook for 2025 and target FCF to 2027 mostly reflect a much better 1H25 in quantum, but also the confidence that is building up in which problematic areas are being turned around. The UK is looking to integrate in 2H no less than two acquisitions, while China deals with lower interest rates and has upped again its dividends (where AGEAS collects c.25%). Looking ahead, if ETHIAS was to come to the market, the challenge will be to win a bid over banks that will have the Danish compromise cap...
1H25 revenues landed at €6.5m growing 12% y/y (26% h/h) below our €8mE. Gross margins kept up well at a high 60%. Ongoing cost efficiencies show off with FTE's down to 154 vs. 169 at year end. EBITDA stood at €-8.2m (vs. €-6.4m in 1H24 and our €-6.9mE). Guidance remained unchanged calling for FY25 revenues to grow in the 50-70% range. We are currently at the mid point of this range. In order to reach this forecast, 2H25 revenues should grow >115% y/y and >70% sequentially (h/h). We remain cautio...
The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film Regulated information August 27, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film Group performance: Strong HealthCare IT performance and stable Digital Print & Chemicals performance not sufficiently offsetting the continued fast decline in medical filmAdjusted EBITDA decreased...
De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestatie HealthCare IT, stabiele prestatie Digital Print & Chemicals – verdere achteruitgang medische film Gereglementeerde informatie 27 augustus 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestatie HealthCare IT, stabiele prestatie Digital Print & Chemicals – verdere achteruitgang medische film Groepsprestatie: Sterke prestatie van HealthCare IT en stabiele prestatie van Digital Print & Chemicals volstaan niet om de ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.